Last updated on August 2018

Safety and Biological Activity of Vesatolimod in HIV-1 Infected Virologically Suppressed Adults

Brief description of study

The primary objectives of this study are to evaluate the safety and tolerability of a 6-dose regimen of vesatolimod (formerly GS-9620) (at 1 mg, 2 mg, and 4 mg dose levels) in HIV-1 infected virologically suppressed adults on antiretroviral therapy (ART) and to evaluate the virologic effect of vesatolimod as measured by changes in plasma HIV-1 RNA.

Clinical Study Identifier: NCT02858401

Contact Investigators or Research Sites near you

Start Over

Anthony Mills, MD

Mills Clinical Research
Los Angeles, CA United States

Constance A Benson, MD

UCSD Antiviral Research Center (AVRC)
San Diego, CA United States

Michael F. Para, MD

Ohio State University Infectious Diseases Research
Columbus, OH United States

Sharon Anne Riddler, MD

University of Pittsburgh
Pittsburgh, PA United States